60 Degrees Pharmaceuticals’ (SXTP) “Sell (E+)” Rating Reaffirmed at Weiss Ratings

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “sell (e+)” rating restated by equities researchers at Weiss Ratings in a research note issued to investors on Saturday,Weiss Ratings reports.

Separately, HC Wainwright restated a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a report on Friday, January 10th.

60 Degrees Pharmaceuticals Price Performance

Shares of NASDAQ:SXTP traded up $0.00 during trading hours on Friday, hitting $0.83. The company’s stock had a trading volume of 322,501 shares, compared to its average volume of 926,419. The company has a market capitalization of $1.90 million, a price-to-earnings ratio of -0.08 and a beta of 4.40. 60 Degrees Pharmaceuticals has a 52 week low of $0.70 and a 52 week high of $11.01. The firm’s fifty day moving average price is $1.19 and its 200 day moving average price is $1.02.

Insider Activity

In other news, CEO Geoffrey S. Dow bought 35,823 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The stock was purchased at an average price of $1.27 per share, with a total value of $45,495.21. Following the completion of the acquisition, the chief executive officer now directly owns 94,580 shares of the company’s stock, valued at $120,116.60. This trade represents a 60.97 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders acquired 66,372 shares of company stock worth $82,410. Insiders own 10.27% of the company’s stock.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.